Evidence map›Paper›PMID 42629514›Full record

ArticleJournal of neuro-oncology2026

Five-year changes in health-related quality of life after proton therapy in a primarily meningioma cohort: a prospective study.

Per Fessé, Linda Åkeflo, Karin Ahlberg, Emelie Blomqvist, Per Fransson, Ingrid Kristensen, Kristin Kunni, Ulrica Langegård, Emma Ohlsson-Nevo, Katarina Sjövall

Abstract read
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Per FesséInstitute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Box 457, Gothenburg, SE- 405 30, Sweden. per.fesse@gu.se.ORCID http://orcid.org/0000-0002-0005-2500
Linda ÅkefloInstitute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Box 457, Gothenburg, SE- 405 30, Sweden.ORCID http://orcid.org/0000-0002-6795-1092
Karin AhlbergInstitute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Box 457, Gothenburg, SE- 405 30, Sweden.ORCID http://orcid.org/0000-0001-9430-0589
Emelie BlomqvistInstitute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Box 457, Gothenburg, SE- 405 30, Sweden.ORCID http://orcid.org/0009-0000-8633-2919
Per FranssonDepartment of Nursing, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0002-1248-5581
Ingrid KristensenRadiation Physics, Department of Haematology, Oncology and Radiation Physics, Lund University Hospital, Lund, Sweden.ORCID http://orcid.org/0000-0002-2742-0887
Kristin KunniSkandion Clinic, Uppsala, Sweden.ORCID http://orcid.org/0009-0000-8286-2082
Ulrica LangegårdInstitute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Box 457, Gothenburg, SE- 405 30, Sweden.ORCID http://orcid.org/0000-0001-8174-579X
Emma Ohlsson-NevoDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID http://orcid.org/0000-0001-6185-2328
Katarina SjövallFaculty of Health Sciences, Kristianstad University, Kristianstad, Sweden.ORCID http://orcid.org/0000-0001-7186-9051

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLong-term patient-reported outcomes after Proton beam therapy (PBT) remain insufficiently described for patients with benign intracranial and seller-region tumors. The aim of this study was to evaluate health-related quality of life (HRQoL) and brain tumor-specific symptoms over five years after PBT in a primarily meningioma cohort.

methodsIn this prospective cohort study, adults treated with PBT completed the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-BN20 questionnaires from baseline through 5 years. Mixed models for repeated measures estimated mean scores and change from baseline with 95% confidence intervals. Baseline-to-five-year change analyses included participants with available data at both time points. Exploratory analyses evaluated associations between sociodemographic factors and changes over five-years.

resultsSeventy-seven of 126 participants (61%) completed the 5-year assessment. Global health status did not change significantly, whereas the QLQ-C30 summary score declined modestly. Clinically meaningful worsening was observed for fatigue and insomnia, with smaller increases in pain, dyspnoea, and constipation. Physical and cognitive functioning declined, while emotional functioning improved. On the QLQ-BN20, hair loss increased to a clinically meaningful extent and drowsiness, bladder control difficulties, motor dysfunction, communication deficits, and leg weakness worsened, whereas headaches decreased. No associations were observed between the investigated sociodemographic factors and change in fatigue or insomnia.

conclusionsFive-year outcomes demonstrated a mixed pattern with stable global health status despite a modest decline in overall HROoL and worsening in several symptom and functioning domains. Clinically meaningful increases in fatigue and insomnia, alongside smaller functional and brain tumor-specific changes, support structured long-term follow-up and rehabilitation. These findings reflect long-term outcomes following PBT, while treatment-specific contribution remains uncertain.

Indexed as

Meningeal NeoplasmsMeningiomaProton TherapyQuality of LifeAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPatient Reported Outcome MeasuresProspective StudiesSurveys and QuestionnairesMeningiomaPatient-reported outcomes and Health-related quality of lifeProton beam therapy

Identifiers

PMID42629514
PMCPMC13498638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.